Investment Analysts’ Weekly Ratings Changes for LifeMD (LFMD)

by · The Markets Daily

LifeMD (NASDAQ: LFMD) recently received a number of ratings updates from brokerages and research firms:

  • 12/8/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/1/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/25/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/24/2025 – LifeMD was given a new $8.00 price target on by analysts at Loop Capital.
  • 11/22/2025 – LifeMD was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
  • 11/20/2025 – LifeMD was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
  • 11/19/2025 – LifeMD had its price target lowered by analysts at HC Wainwright from $13.00 to $9.00. They now have a “buy” rating on the stock.
  • 11/19/2025 – LifeMD had its price target lowered by analysts at KeyCorp from $12.00 to $8.00. They now have an “overweight” rating on the stock.
  • 11/19/2025 – LifeMD had its price target lowered by analysts at Mizuho from $8.00 to $6.00. They now have a “neutral” rating on the stock.
  • 11/18/2025 – LifeMD had its price target lowered by analysts at Lake Street Capital from $14.00 to $8.00. They now have a “buy” rating on the stock.
  • 11/18/2025 – LifeMD had its price target lowered by analysts at B. Riley from $12.00 to $10.00. They now have a “buy” rating on the stock.
  • 11/18/2025 – LifeMD had its price target lowered by analysts at BTIG Research from $18.00 to $10.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, CMO Jessica Friedeman sold 15,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $3.61, for a total value of $54,150.00. Following the transaction, the chief marketing officer owned 205,000 shares of the company’s stock, valued at approximately $740,050. The trade was a 6.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 18.40% of the company’s stock.

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

See Also